Psychische Erkrankungen und Immunsystem

Zusammenfassung

Die Veränderungen von Immunfunktionen im Zusammenhang mit psychischen Erkrankungen haben im vergangenen Jahrzehnt zunehmende wissenschaftliche Aufmerksamkeit erregt. Inzwischen konnten für die weitere Forschung wegweisende, wenn auch nicht unumstrittene Befunde insbesondere zu Depressionserkrankungen und Schizophrenien erhoben werden. In der vorliegenden Arbeit wird auf diese Befunde im Detail Bezug genommen; zusätzlich werden Beobachtungen bei postraumatischen Belastungsstörungen sowie Panik- und Zwangsstörungen referiert. Auf dieser Grundlage werden Überlegungen zu weiterführenden Forschungsperspektiven angestellt.

Abstract

Immunological alterations in psychiatric disorders have gained increasing scientific attention throughout the last decade. Particularly in two disorders, major depression and schizophrenia, some substantial findings have been reported. Although such results stand not uncontradicted, they nevertheless stimulate current research into the neurobiological underpinnings of these diseases. In this review, immunological dysfunctions in major depression and schizophrenia are described in detail, together with studies on posttraumatic stress disorders, panic- and obsessive-compulsive disorders. Possible future research directions are delineated.

Immunology - cytokine - depression - posttraumatic stress disorder - anxiety - schizophrenia

Literatur

• 1 Arolt V, Rothermundt M, Peters M, Leonard B. Immunological research in clinical psychiatry: report on the consensus debate during the 7^th Expert Meeting on Psychiatry and Immunology.  Mol Psychiatry. 2002;  7 822-826
• 2 Bartrop R W, Lazarus L, Luckhurst E, Kiloh L G. Depressed lymphocyte function after bereavement.  Lancet. 1977;  83 834-836
• 3 Marazitti D, Ambrogi F, Vanacore R. et al . Immune cell imbalance in major depressive and panic disorders.  Neuropsychobiol. 1992;  26 23-26
• 4 Müller N, Hofschuster E, Ackenheil M. et al . Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis.  Progr Neuropsychopharmacol Biol Psychiatry. 1993;  17 713-730
• 5 Legros S, Mendlewicz J, Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders.  Eur Arch Psychiatry Clin Neurosci. 1985;  235 9-11
• 6 Seidel A, Arolt V, Hunstiger M. et al . Cytokine production and serum proteins in depression.  Scand J Immunol. 1995;  41 534-538
• 7 Berk M, Wadee A A, Kuschke R H, O'Neill-Kerr A. Acute phase proteins in major depression.  J Psychosom Res. 1997;  43 529-534
• 8 Joyce P R, Hawes C R, Mulder R T. et al . Elevated levels of acute phase proteins in major depression.  Biol Psychiatry. 1992;  32 1035-1041
• 9 Maes M, Scharpe S, Bosmans E. et al . Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness.  Progr Neuropsychopharmacol Biol Psychiatry. 1992 a;  16 501-515
• 10 Maes M, Delanghe J, Ranjan R. et al . Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs.  Psychiatry Res. 1997 c;  66 1-11
• 11 Song C, Dinan T, Leonard B E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls.  J Affect Disord. 1994;  30 283-288
• 12 Maes M, Planken M Van der, Stevens W J. et al . Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression.  J Psychiatr Res. 1992 c;  26 125-134
• 13 Seidel A, Arolt V, Hunstiger M. et al . Major depressive disorder is associated with elevated monocyte counts.  Acta Psychiatr Scand. 1996 a;  94 198-204
• 14 Castilla-Cortazar I, Castilla A, Gurpegi M. Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders.  J Physiol Biochem. 1998;  54 203-215
• 15 Irwin M, Smith T L, Gillin J C. Low natural killer cytotoxicity in major depression.  Life Sci. 1987;  41 2127-2133
• 16 Darko D F, Gillin J C, Risch S C. et al . Immune Cells and the Hypothalamic-Pituitary Axis in Major Depression.  Psychiatry Res. 1988;  25 173-179
• 17 Maes M, Meltzer H Y, Stevens W. et al . Natural Killer Cell Activity In Major Depression: Relation To Circulating Natural Killer Cells, Cellular Indices Of The Immune Response, And Depressive Phenomenology.  Progr Neuropsychopharmacol Biol Psychiatry. 1994 c;  18 717-730
• 18 Anesi A, Franciotta D, Paolo E Di. et al . PHA-Stimulated Cellular Immune Function And T-Lymphocyte Subsets In Major Depressive Disorders.  Funct Neurol. 1994;  9 17-22
• 19 McAdams C, Leonard B E. Neutrophil and monocyte phagocytosis in depressed patients.  Progr Neuropsychopharmacol Biol Psychiatry. 1993;  17 971-984
• 20 Maes M, Bosmans E, Suy E. et al . Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1beta and soluble interleukin-2 receptor production.  Acta Psychiatr Scand. 1991 a;  84 379-386
• 21 Maes M, Bosmans E, Meltzer H Y. et al . Interleukin-1beta: A putative mediator of HPA axis hyperactivity in major depression?.  Am J Psychiatry. 1993 a;  150 1189-1193
• 22 Weizman R, Laor N, Podliszewski E. et al . Cytokine production in major depressed patients before and after clomipramine treatment.  Biol Psychiatry. 1994;  35 42-47
• 23 Maes M, Meltzer H Y, Bosmans E. et al . Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.  J Affect Dis. 1995 b;  34 301-309
• 24 Maes M, Bosmans E, Jongh R de . et al . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.  Cytokine. 1997 a;  9 853-858
• 25 Haack M, Hinze-Selch D, Fenzel T. et al . Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.  J Psychiatr Res. 1999;  33 407-418
• 26 Maes M, Meltzer H Y, Buckley P, Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.  Eur Arch Psychiatry Clin Neurosci. 1995c;  244 325-329
• 27 Maes M. Evidence for an immune response in major depression: a review and hypothesis.  Progr Neuropsychopharmacol Biol Psychiatry. 1995 d;  19 11-38
• 28 Anisman H, Ravindran A V, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features.  Mol Psychiatry. 1999;  4 182-188
• 29 Darko D F, Gillin J C, Risch S C. et al . Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression.  Biol Psychiatry. 1989;  26 145-155
• 30 Natelson B H, Denny T, Zhou X D. et al . Is depression associated with immune activation?.  J Affect Disord. 1999;  53 179-184
• 31 Inglot A D, Leszek J, Piasecki E, Sypula A. Interferon responses in schizophrenia and major depressive disorders.  Biol Psychiatry. 1994;  35 464-473
• 32 Maes M, Scharpe S, Meltzer H Y. et al . Increased neopterin and interferon-gamma secretion and lower avaibility of l-tryptophan in major depression: further evidence for an immune response.  Psychiatry Res. 1994 d;  54 143-160
• 33 Seidel A, Arolt V, Hunstiger M. et al . Increased CD56+Natural Killer Cells and Related Cytokines in Major Depression.  Clin Immunol Immunopathol. 1996 b;  78 83-85
• 34 Rothermundt M, Arolt V, Fenker J. et al . Different immune patterns in melancholic and non-melancholic major depression.  Eur Arch Psychiatry Clin Neurosci. 2001 b;  251 90-97
• 35 Rothermundt M, Arolt V, Peters M. et al . Inflammatory markers in major depression and melancholia.  J Affect Disord. 2001 c;  63 93-102
• 36 Konsman J P, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications.  Trends Neurosci. 2002;  25 154-159
• 37 Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.  Gen Hosp Psychiatry. 2003;  25 34-38
• 38 Capuron L, Ravaud A, Neveu P J. et al . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.  Mol Psychiatry. 2002 b;  7 468-473
• 39 Widner B, Laich A, Sperner-Unterweger B. et al . Neopterin production, tryptophan degradation, and mental depression - what is the link?.  Brain Behav Immun. 2002;  16 590-595
• 40 Reichenberg A, Yirmiya R, Schuld A. et al . Cytokine-associated emotional and cognitive disturbances in humans.  Arch Gen Psychiatry. 2001;  58 445-452
• 41 Pollmächer T, Haack M, Schuld A. et al . Low levels of circulating inflammatory cytokines - Do they affect human brain functions?.  Brain Behav Immun. 2002;  16 525-532
• 42 Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for „free chow” and „earned” sucrose intake.  Psychopharmacol. 2003;  165 413-418
• 43 Capuron L, Gumnick J F, Musselman D L. et al . Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.  Neuropsychopharmacol. 2002 a;  26 643-652
• 44 Wong C M. Post-traumatic stress disorder: advances in psychoneuroimmunology.  Psychiatr Clin North Am. 2002;  25 369-383
• 45 Boscarino J A, Chang J. Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications.  Psychosom Med. 1999;  61 378-386
• 46 Weiss D W, Hirt R, Tarcic N. et al . Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks.  Behavioral Med. 1996;  22 5-14
• 47 Wilson S N, Kolk B van der, Burbridge J. et al . Phenotype of blood lymphocytes in PTSD suggests chronic immune activation.  Psychosomatics. 1999;  40 222-225
• 48 Laudenslager M L, Aasal R, Adler L. et al . Elevated cytotoxicity in combat veterans with long-term post-traumatic stress disorder: preliminary observations.  Brain Behav Immun. 1998;  12 74-79
• 49 Watson I P, Muller H K, Jones I CH, Bradley A J. Cell-mediated immunity in combat veterans with post-traumatic stress disorder.  Med J Australia. 1993;  159 513-516
• 50 Gotovac K, Sabioncello A, Rabatic S. et al . Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD).  Clin Exp Immunol. 2003;  131 335-339
• 51 Maes M, Lin A H, Delmeire L. et al . Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events.  Biol Psychiatry. 1999 a;  45 833-839
• 52 Lehmann-Facius H. Liquoruntersuchungen bei destruktiven Erkrankungen des Nervensystems, besonders bei Schizophrenien.  Neurologie Psychiatrie. 1937;  157 109-115
• 53 Torrey E F, Miller J, Rawlings R, Yolken R H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature.  Schizophr Res. 1997;  28 1-38
• 54 Wright P, Gill M, Murray R M. Schizophrenia: Genetics and the maternal immune response to viral infection.  Am J Med Gen. 1993;  48 40-46
• 55 Kirch D G. Infection and autoimmunity as etiologic factors in schizophrenia: A review and reappraisal.  Schizophr Bull. 1993;  19 355-370
• 56 Rothermundt M, Arolt V, Bayer T A. Review of immunological and immunopathological findings in schizophrenia.  Brain Behav Immun. 2001 a;  15 319-339
• 57 Ganguli R, Rabin B S. Increased serum interleukin-2 receptor in schizophrenic and brain damaged subjects.  Arch Gen Psychiatry. 1989;  46 291-292
• 58 Rapaport M H, McAllister C G, Pickar D. et al . Elevated levels of soluble interleukin-2 receptors in schizophrenia.  Arch Gen Psychiatry. 1989;  46 291-292
• 59 Hornberg M, Arolt V, Wilke I. et al . Lymphokine production in leukocyte cultures of patients with schizophrenia.  Schizophr Res. 1995;  15 237-242
• 60 McAllister C G, Kammen D P van, Rehn T J. et al . Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.  Am J Psychiatry. 1995;  152 1291-1297
• 61 Rapaport M H, Lohr J B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.  Acta Psychiatr Scand. 1994;  90 311-315
• 62 Schwarz M J, Ackenheil M, Riedel M, Müller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia.  Neurosci Lett. 1998;  253 201-203
• 63 Müller N, Riedel M, Hadjamu M. et al . Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia.  Am J Psychiatry. 1999 b;  156 634-636
• 64 Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders.  Progr Neuropsychopharmacol Biol Psychiatry. 1998;  22 1-33
• 65 Müller N, Riedel M, Ackenheil M, Schwarz M J. The role of immune function in schizophrenia: an overview.  Eur Arch Psychiatry Clin Neurosci. 1999 a;  249, Suppl 4 62-68
• 66 Moises H W, Schindler L, Leroux M, Kirchner H. Decreased production of interferon alpha and interferon gamma in leukocyte cultures of schizophrenic patients.  Acta Psychiatr Scand. 1985;  72 45-50
• 67 Villemain F, Chatenoud L, Guillibert E. et al . Decreased production of interleukin-2 in schizophrenia.  Ann N Y Acad Sci. 1987;  469 669-675
• 68 Villemain F, Chatenoud L, Galinowski A. et al . Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production.  Am J Psychiatry. 1989;  146 609-616
• 69 Ganguli R, Rabin B S, Belle S H. Decreased interleukin-2 production in schizophrenic patients.  Biol Psychiatry. 1989;  26 427-430
• 70 Licinio J, Seibyl J P, Altemus M. et al . Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients.  Am J Psychiatry. 1993;  150 1408-1410
• 71 El-Mallakh R S, Suddath R L, Wyatt R J. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.  Prog Neuropsychopharmacol Biol Psychiatry. 1993;  17 383-391
• 72 Barak V, Barak Y, Levine J. et al . Changes in interleukin-1beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients.  J Basic Clin Physiol Pharmacol. 1995;  6 61-69
• 73 Rapaport M H, McAllister C G, Pickar D. et al . CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.  Schizophr Res. 1997;  25 123-129
• 74 Wilke I, Arolt V, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenics.  Eur Arch Psychiatry Clin Neurosci. 1996;  246 279-284
• 75 Rothermundt M, Arolt V, Weitzsch C. et al . Decreased production of IFN-γ in acute schizophrenia.  Biol Psychiatry. 1996;  40 1294-1297
• 76 Rothermundt M, Arolt V, Weitzsch C. et al . Immunological dysfunction in schizophrenia: a systematic approach.  Neuropsychobiol. 1998;  37 186-193
• 77 Rothermundt M, Arolt V, Leadbeater J. et al . Cytokine production in unmedicated and treated schizophrenic patients.  Neuroreport. 2000;  11 3385-3388
• 78 Arolt V, Weitzsch C, Wilke I. et al . Production of interferon-gamma in families with multiple occurrence of schizophrenia.  Psychiatry Res. 1997 a;  66 145-151
• 79 Arolt V, Rothermundt M, Wandinger K P, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment.  Mol Psychiatry. 2000;  5 150-158
• 80 Sivieri S, Ferrarini A M, Gallo P. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.  Mult Sclerosis. 1998;  4 7-11
• 81 Schwarz M J, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders.  Brain Behav Immun. 2001;  15 340-370
• 82 Andreoli A V, Keller S E, Rabaeus M. et al . Immunity, major depression, and panic disorder comorbidity.  Biol Psychiatry. 1992;  31 896-908
• 83 Surman O S, Williams J, Sheehan D V. et al . Immunological response to stress in agoraphobia and panic attacks.  Biol Psychiatry. 1986;  21 768-774
• 84 Brambilla F, Bellodi L, Perna G. et al . Psychoimmunoendocrine aspects of panic disorder.  Neuropsychobiol. 1992;  26 12-22
• 85 Koh K B, Lee B K. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders.  Psychosom Med. 1998;  60 479-483
• 86 Rapaport M H. Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers.  Biol Psychiatry. 1998;  43 458-463
• 87 Rapaport M H, Stein M B. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia.  Anxiety. 1994 a;  1 50-53
• 88 Rapaport M H, Stein M B. Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder.  Anxiety. 1994 b;  1 22-25
• 89 Weizman R, Laor N, Wiener Z. et al . Cytokine production in panic disorder patients.  Clin Neuropharmacol. 1999;  22 107-109
• 90 Barber Y, Toren P, Achiron A. et al . T cell subsets in obsessive-compulsive disorder.  Neuropsychobiol. 1996;  34 63-66
• 91 Ravindran A V, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls.  J Affect Disord. 1999;  52 1-10
• 92 Maes M, Meltzer H Y, Bosmans E. Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations.  Neuropsychobiol. 1994 b;  30 57-60
• 93 Monteleone P, Catapone F, Fabrazzo M. et al . Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder.  Neuropsychobiol. 1998;  37 182-185
• 94 Weizman R, Laor N, Barber Y. et al . Cytokine production in obsessive-compulsive disorder.  Biol Psychiatry. 1996;  40 908-912
• 95 Arolt V, Weitzsch C, Rothermundt M. et al . Interferon-gamma in schizophrenia.  Recent Adv Biol Psychiatry. 1997 b;  18 57-66
• 96 Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol.  Immunopharmacol. 1997;  37 75-86
• 97 Nozaki H, Hozumi K, Nishimura T, Habu S. Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice.  Brain Behav Immunity. 1996;  10 17-26
• 98 Maes M, Bosmans E, Calabrese J. et al . Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.  J Psychiatr Res. 1995 a;  29 141-152
• 99 Müller N, Empl M, Riedel M. et al . Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 308-313
• 100 Pollmächer T, Hinze-Selch D, Fenzel T. et al . Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.  Am J Psychiatry. 1997 b;  154 1763-1765
• 101 Ghosh N, Chattopadhyay U. Enhancement of immune response by phenothiazine administration in vivo.  In vivo. 1993;  7 435-440
• 102 Tarazona R, Gonzales-Garcia A, Zamzami N. et al . Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo.  J Immunol. 1995;  154 861-870
• 103 Bessler H, Levental Z, Karp L. et al . Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.  Biol Psychiatry. 1995;  38 297-302
• 104 Ganguli R, Bra J S, Solomon W. et al . Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production.  Psychiatry Res. 1992;  44 113-123
• 105 Rudolf S, Peters M, Rothermundt M. et al . The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro.  Neuropsychobiol. 2002;  46 180-181
• 106 Maes M, Bosmans E, Ranjan R. et al . Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs.  Schizophr Res. 1996;  21 39-50
• 107 Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.  J Clin Psychopharmacol. 1996;  16 403-409
• 108 Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.  Pharmacopsychiatry. 1997 a;  30 118-121
• 109 Maes M, Meltzer H Y, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.  Acta Psychiatr Scand. 1994 a;  89 346-351
• 110 Maes M, Bosmans E, Kenis G. et al . In vivo immunomodulatory effects of clozapine in schizophrenia.  Schizophr Res. 1997 b;  26 221-225
• 111 Hinze-Selch D, Becker E W, Stein G M. et al . Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients.  Neuropsychopharmacol. 1998;  19 114-122
• 112 Monteleone P, Fabrazzo M, Tortolla A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.  Psychiatry Res. 1997;  71 11-17
• 113 Kubera M, Basta-Kaim A, Skowron-Cendrzak A. et al . Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity.  Pol J Pharmacol. 1995;  47 321-326
• 114 Kubera M, Symbirtsev A, Basta-Kaim A. et al . Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression.  Pol J Pharmacol. 1996;  48 503-506
• 115 Sacerdote P, Bianchi M, Panerai A E. In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat.  Eur J Pharmacol. 1997;  319 287-290
• 116 Eisen J N, Irwin J, Quay J, Livnat S. The effect of antidepressants on immune function in mice.  Biol Psychiatry. 1989;  26 805-817
• 117 Henderson D C, Edwards R G, Weston B J, Dewdney J M. Immunological studies on paroxetine, a novel anti-depressant drug.  Int J Immunopharmacol. 1998;  10 361-367
• 118 Xiao L, Eneroth P. Tricyclic antidepressants inhibit human natural killer cells.  Toxicol Appl Pharmacol. 1996;  137 157-162
• 119 Xia Z, DePierre J W, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells.  Immunopharmacol. 1996;  34 27-37
• 120 Miller A H, Asnis G M, Praag H M van, Norin A J. Influence of desmethylimipramine on natural killer cell activity.  Psychiatry Res. 1986;  19 9-15
• 121 Maes M, Song C, Lin A H. et al . Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.  Neuropsychopharmacol. 1999 b;  20 370-379
• 122 Pariante C M, Miller A H. Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment.  Eur Neuropsychopharmacol. 1995;  5, Suppl 83-88
• 123 Landmann R, Schaub B, Link S, Wacher H R. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy.  Biol Psychiatry. 1997;  41 675-681
• 124 Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract.  J Geriatr Psychiatry Neurol. 1994;  7, Suppl 1 60-62
• 125 Ravindran A V, Griffiths J, Merali Z, Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment.  Psychosom Med. 1995;  57 555-563
• 126 Sluzewska A, Rybakowski J K, Laciak M. et al . Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.  Ann N Y Acad Sci. 1995;  762 474-476
• 127 Andreoli A V, Keller S E, Rabaeus M C. et al . Depression and Immunity: Age, Severity, and Clinical Course.  Brain Behav Immun. 1993;  7 279-292
• 128 Bauer M E, Gauer G J, Luz C. et al . Evaluation of immune parameters in depressed Patients.  Life Sci. 1995;  57 665-674
• 129 Caldwell C L, Irwin M, Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia.  Biol Psychiatry. 1991;  30 1131-1138
• 130 Castle S, Wilkins S, Heck E. et al . Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+ CD8+).  Clin Exp Immunol. 1995;  101 487-493
• 131 Evans D L, Folds J D, Petitto J M. et al . Circulating Natural Killer Cell Phenotypes in Men and Women With Major Depression.  Arch Gen Psychiatry. 1992;  49 388-395
• 132 Hickie I, Hickie C, Lloyd A. et al . Impaired in vivo immune responses in patients with melancholia.  Br J Psychiatry. 1993;  162 651-657
• 133 Irwin M, Patterson T, Smith T L. et al . Reduction of immune function in life stress and depression.  Biol Psychiatry. 1990;  27 22-30
• 134 Kanba S, Manki H, Shintani F. et al . Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode.  Psychol Med. 1998;  28 481-484
• 135 Kook A I, Mizruchin A, Odnopozov N. et al . Depression and immunity: the biochemical interrelationship between the central nervous system and the immune system.  Biol Psychiatry. 1995;  37 817-819
• 136 Levy E M, Borrelli D J, Mirin S M. et al . Biological Measures and Cellular Immunological Function in Depressed Psychiatric Inpatients.  Psychiatry Res. 1991;  36 157-167
• 137 Maes M, Bosmans E, Suy E. et al . A further exploration of the relationships between immune parameters and the HPA-axis activity in depressed patients.  Psychol Med. 1991 b;  21 313-320
• 138 Maes M, Stevens W, Peeters D. et al . A Study On The Blunted Natural Killer Cell Activity In Severely Depressed Patients.  Life Sci. 1992 b;  50 505-513
• 139 Maes M, Scharpe S, Meltzer H Y, Cosyns P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression.  Biol Psychiatry. 1993 b;  34 690-701
• 140 Miller A H, Asnis G M, Lackner C. et al . Depression, natural killer cell activity, and cortisol secretion.  Biol Psychiatry. 1991;  29 878-886
• 141 Natelson B H, LaManca J J, Denny T N. et al . Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis.  Am J Med. 1998;  105 43S-49S
• 142 Ravindran A V, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features.  Psychosom Med. 1998;  60 283-289
• 143 Reynaert C, Janne P, Bosly A. et al . From health locus of control to immune control: internal locus of control has a buffering effect on natural killer cell activity decrease in major depression.  Acta Psychiatr Scand. 1995;  92 294-300
• 144 Schleifer S J, Keller S E, Bartlett J A. et al . Immunity in Young Adults With Major Depressive Disorder.  Am J Psychiatry. 1996;  153 477-482
• 145 Spurrell M T, Creed F H. Lymphocyte response in depressed patients and subjects anticipating bereavement.  Br J Psychiatry. 1993;  162 60-64
• 146 Wodarz N, Rupprecht R, Kornhuber J. et al . Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression.  J Affect Disord. 1991;  22 241-248